TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22460385

Group type: EXPERIMENTAL
Intervention: Composite 20% IVFE (composed of soybean, MCT, olive, and fish oils)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional long-chain triglyceride (LCT)/MCT 20% IVFE
Number of subjects: 40
Study: 20541381

Group type: EXPERIMENTAL
Intervention: NVA237 50 microg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: NVA237 100 microg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 18678842

Group type: EXPERIMENTAL
Intervention: Rapid HIV testing with the OraQuick ADVANCE Rapid HIV‐1/2 Antibody Test
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Western blot alone as a confirmation test
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Addition of HIV‐1 RNA testing to the confirmation protocol
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Reactive oral OraQuick HIV screening test
Number of subjects: 849
Study: 16227898

Group type: EXPERIMENTAL
Intervention: Nursing school entry back pain history
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: First year in nursing school
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: First year as a nurse
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fifth year as a nurse
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Back pain history at entry to nursing school
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Working in twisted/bent positions
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Working positions
Number of subjects: 174
Study: 12892186

Group type: EXPERIMENTAL
Intervention: Bilateral THR
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unilateral THR
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cemented THR
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cementless THR
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Thrombi at six months
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pulmonary embolism
Number of subjects: 200
Study: 10223771

Group type: EXPERIMENTAL
Intervention: 800 mg oral ibuprofen
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 16 g of 5% ibuprofen gel (topical administration)
Number of subjects: 11
Study: 8874256

Group type: EXPERIMENTAL
Intervention: Supervised physical training program using a bicycle ergometer for 30 min 3 times a week at a load corresponding to 50 to 60% of peak oxygen consumption
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Supervised physical training program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no change in previous physical activity)
Number of subjects: 27
Study: 1997515

Group type: EXPERIMENTAL
Intervention: 13‐min insulin pulses (1.3 mU kg‐1 min‐1, 2 min on and 11 min off)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 26‐min insulin pulses (2.6 mU kg‐1 min‐1, 2 min on and 24 min off)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Continuous insulin (0.2 mU kg‐1 min‐1)
Number of subjects: 9
Study: 6555065

Group type: EXPERIMENTAL
Intervention: Dexamethasone administration for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group with normal sodium intake
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group with low sodium intake
Number of subjects: 12
Study: 31242981

Group type: EXPERIMENTAL
Intervention: Tualang honey 20mg daily for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vitamin C 100mg daily for 8 weeks
Number of subjects: 40
Study: 28623766

Group type: EXPERIMENTAL
Intervention: Telehomecare technology
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no telehomecare technology)
Number of subjects: 116
Study: 27206952

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day (MARINE)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day (ANCHOR)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day (ANCHOR, higher-efficacy group)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/day (ANCHOR, medium-efficacy group)
Number of subjects: 760
Study: 24844333

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1126
Study: 21738241

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surgical weight loss (gastric bypass)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 19514187

Group type: EXPERIMENTAL
Intervention: NGF injection at Yifeng (TE 17) and Wangu (GB 12)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Xibiling and adenosine triphosphate (ATP) orally, and intramuscular injection with VB1 and VB12
Number of subjects: 140
Study: 17766700

Group type: COMPARATOR
Intervention: Enzastaurin (single doses 2-400 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Enzastaurin (multiple doses 25-400 mg)
Number of subjects: 46
Study: 15801497

Group type: EXPERIMENTAL
Intervention: Modified-implement training (bowling with overweight and underweight cricket balls)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional training (bowling with regulation cricket balls)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modified-implement training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 16
Study: 11526657

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Thrombolysis (Control)
Number of subjects: 96
Study: 9561984

Group type: EXPERIMENTAL
Intervention: MRI studies in patients with LNS
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Volumetric studies of patients with LNS
Number of subjects: 7
Study: 7909866

Group type: EXPERIMENTAL
Intervention: Postoperative treatment with 500 mg of 17‐1A antibody, followed by four 100 mg infusions each month
Number of subjects: 189
Study: 3108534

Group type: EXPERIMENTAL
Intervention: Intralipid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Soyacal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both lipid emulsions
Number of subjects: 18
Study: 29869350

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 70
Study: 27451879

Group type: EXPERIMENTAL
Intervention: Rikkunshito (2.5 g before every meal for 48 weeks)
Number of subjects: 40
Study: 23983196

Group type: EXPERIMENTAL
Intervention: Joint distraction
Number of subjects: 111
Study: 22419702

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg two times daily for obese women; 500 mg + 1000 mg daily for nonobese)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo (identical doses)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Metformin (in obese women)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo (in obese women)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Metformin (in nonobese women)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo (in nonobese women)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Metformin plus standard infertility treatment
Number of subjects: 320
Study: 19669678

Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly administration)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ranibizumab (as-needed basis)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pegaptanib
Number of subjects: 2
Study: 18441450

Group type: EXPERIMENTAL
Intervention: Fluvastatin (group A)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bezafibrate (group B)
Number of subjects: 93
Study: 16192479

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg per day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg every 12 hours)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: All groups post-surgery
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 95
Study: 12761364

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 132
Study: 10823763

Group type: EXPERIMENTAL
Intervention: Discontinuation of prophylaxis (n=355)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Continuation of prophylaxis (n=353)
Number of subjects: 708
Study: 8651713

Group type: EXPERIMENTAL
Intervention: 8% glycolic acid cream
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 8% L-lactic acid cream
Number of subjects: 74

Group type: COMPARATOR
Intervention: vehicle cream
Number of subjects: 74
Study: 1995051

Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5 mg/kg intravenously prior to induction
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no lignocaine)
Number of subjects: 15
Study: 6400414

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo plasma exchange
Number of subjects: 6
Study: 31722941

Group type: EXPERIMENTAL
Intervention: Loading dose of 540,000 IU cholecalciferol followed by 4000 IU daily for 90 days
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study: 30371293

Group type: EXPERIMENTAL
Intervention: ACEI/ARB continuation
Number of subjects: 126
Study: 26597254

Group type: EXPERIMENTAL
Intervention: Artesunate/Amodiaquine (AS/AQ)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Artemether/Lumefantrine (AL)
Number of subjects: 602
Study: 24838369

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg of ethanol
Number of subjects: 65

Group type: COMPARATOR
Intervention: No ethanol
Number of subjects: 65
Study: 22726885

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) administered at a dose of ≥20 UI/kg with vitamin K
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) administered at a dose of >20 UI/kg
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) for major hemorrhages
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) administration
Number of subjects: 256
Study: 20109697

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16889639

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone pulse (IVGC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Oral methylprednisolone (OGC)
Number of subjects: 52
Study: 15953135

Group type: EXPERIMENTAL
Intervention: BNP group (n = 136)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group (n = 133)
Number of subjects: 269
Study: 12519218

Group type: EXPERIMENTAL
Intervention: AOC7 (1000 mg amoxicillin, 20 mg omeprazole, and 500 mg clarithromycin twice daily for 7 days)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: FOT4 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 4 days)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: FOT7 (200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 7 days)
Number of subjects: 128
Study: 10862549

Group type: EXPERIMENTAL
Intervention: Directly supervised heavy-resistance training (SUP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unsupervised training (UNSUP)
Number of subjects: 20
Study: 8892160

Group type: EXPERIMENTAL
Intervention: Behavioral approach
Number of subjects: 48

Group type: COMPARATOR
Intervention: Behavioral approach preceded by surgery
Number of subjects: 48

Group type: COMPARATOR
Intervention: Behavioral approach without preceding surgery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Surgery after failed behavioral treatment
Number of subjects: 48
Study: 2051405

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate introduced below the scleral and conjunctival flaps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no sodium hyaluronate)
Number of subjects: 0
Study: 6209318

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study: 31767474

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with 66 Gy (24x2.75 Gy) and low dose Cisplatin +/− Cetuximab
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Post-treatment PET-metrics (SUVmax, SUVmean, MTV, TLG)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Relative response of TLG/MTV
Number of subjects: 47
Study: 29902612

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 139

Group type: COMPARATOR
Intervention: Regorafenib after cross-over
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Delayed regorafenib
Number of subjects: 139
Study: 28003538

Group type: EXPERIMENTAL
Intervention: Whey Protein supplementation (0, 20, 40, or 60 g WP/d)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Total Protein intake (TPro)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Change in Total Protein intake (postsupplementation - presupplementation)
Number of subjects: 186
Study: 26030325

Group type: EXPERIMENTAL
Intervention: Add-on alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Add-on ezetimibe 10 mg/d
Number of subjects: 355

Group type: COMPARATOR
Intervention: Doubling atorvastatin dose
Number of subjects: 355

Group type: COMPARATOR
Intervention: Switching atorvastatin 40 mg to rosuvastatin 40 mg
Number of subjects: 355
Study: 23988337

Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary care intervention
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 301
Study: 20354035

Group type: EXPERIMENTAL
Intervention: sivelestat 0.2 mg/kg/h
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 12
Study: 18373854

Group type: EXPERIMENTAL
Intervention: High-referring clinicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-referring clinicians
Number of subjects: 0
Study: 17240782

Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey isolate (WI)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Casein (C)
Number of subjects: 13
Study: 12605628

Group type: EXPERIMENTAL
Intervention: Cerebral palsy group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 10706930

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (long‐cycle transdermal 17‐beta‐estradiol 50 microg/24 hour for 3 months with sequential medroxy‐progesterone acetate for 14 days)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 118
Study: 8931030

Group type: EXPERIMENTAL
Intervention: Twice-weekly structured exercise program
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 179
Study: 1442974

Group type: EXPERIMENTAL
Intervention: Levonorgestrel plus ethinyl estradiol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Norethindrone plus ethinyl estradiol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 52
Study: 6430329

Group type: EXPERIMENTAL
Intervention: Amino acids (L‐cysteine, glycine, DL‐threonine)
Number of subjects: 0
Study: 31654294

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg QD
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg BID
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1270
Study: 29692236

Group type: EXPERIMENTAL
Intervention: Cardiac High Acuity Monitoring Program (CHAMP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Three-ring binder monitoring (Binder)
Number of subjects: 31
Study: 27955652

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care in the delivery room
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incubator (standard care)
Number of subjects: 0
Study: 24176943

Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral therapy (ART) during TB treatment
Number of subjects: 501

Group type: COMPARATOR
Intervention: Late initiation of antiretroviral therapy (ART) during TB treatment
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Standard first-line antiretrovirals (efavirenz, lamivudine, didanosine)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Patients with CD4(+) T-cell count <50 cells/mm(3) at ART initiation
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Patients with body mass index >25 kg/m(2) at entry into the study
Number of subjects: 501
Study: 22351711

Group type: EXPERIMENTAL
Intervention: Systematic collection of family history through a questionnaire in intervention practices
Number of subjects: 748

Group type: COMPARATOR
Intervention: Usual Framingham‐based cardiovascular risk assessment without systematic family history collection in control practices
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 748
Study: 20578825

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for one year
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17684221

Group type: EXPERIMENTAL
Intervention: Whole-grain intake
Number of subjects: 28926

Group type: COMPARATOR
Intervention: Refined-grain intake
Number of subjects: 28926
Study: 15892781

Group type: EXPERIMENTAL
Intervention: Synchronized visual-auditory correlations (video of the talker's face synchronized with the target passage)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Unsynchronized visual-auditory correlations (unsynchronized face)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Static visual-auditory correlations (static face)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Synchronized visual-auditory correlations (synchronized oscilloscope pattern)
Number of subjects: 116
Study: 12439223

Group type: EXPERIMENTAL
Intervention: bupropion (300 mg/day for 10 weeks)
Number of subjects: 426

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 426
Study: 9579500

Group type: EXPERIMENTAL
Intervention: Oral clonidine (4 microg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral clonidine (4 microg/kg) with glucose-free solution
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Infusion of 2% glucose with clonidine
Number of subjects: 120
Study: 7650232

Group type: EXPERIMENTAL
Intervention: Venlafaxine (50 mg every 8 hours for 10 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (double‐blind)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg single dose on day 5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 18
Study: 2669089

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 15 mg b.d.
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 975730

Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gm intravenous)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cephalothin (1 gm intravenous)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gm intramuscularly)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cefamandole (2 gm intravenously every 6 hr)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cefamandole (2 gm loading followed by 2 gm every 6 hr)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cephalothin (2 gm loading followed by 2 gm every 6 hr)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cefamandole and Cephalothin (both drugs)
Number of subjects: 32
Study: 31532576

Group type: EXPERIMENTAL
Intervention: V0034CR emollient
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vehicle + glycerol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vehicle + petrolatum
Number of subjects: 51
Study: 30867034

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year
Number of subjects: 2840

Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 2840
Study: 27996097

Group type: EXPERIMENTAL
Intervention: Infection-preventive technique including povidone-iodine, double gloving, meticulous aseptic/antiseptic measures, and antibiotic prophylaxis.
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: New pacemaker implantation
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: New ICD implantation
Number of subjects: 762
Study: 25037727

Group type: EXPERIMENTAL
Intervention: Polypectomy during both insertion and withdrawal phases (study arm)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Withdrawal phase only (control arm)
Number of subjects: 610
Study: 24139127

Group type: EXPERIMENTAL
Intervention: Higenamine-based dietary supplement (including caffeine 270 mg and yohimbe bark extract)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21389299

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (c‐tDCS) of left primary motor cortex (M1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (c‐tDCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonconditioned left BB MEPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipsilateral silent period of left BB
Number of subjects: 0
Study: 19700776

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 50
Study: 17605774

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug via HandiHaler
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 15738750

Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12225474

Group type: EXPERIMENTAL
Intervention: FID EPI sequence
Number of subjects: 60

Group type: COMPARATOR
Intervention: SE EPI sequence
Number of subjects: 60